Bausch + Lomb Expands European IOL Portfolio with enVista Envy Launch
Event summary
- Bausch + Lomb launched the preloaded enVista Envy intraocular lens (IOL) in Europe on April 7, 2026.
- The enVista Envy IOL demonstrated an 86.1% patient satisfaction rate regarding dysphotopsia in a U.S. clinical trial.
- A Canadian study showed 95.4% of patients reported little to no difficulty viewing close objects with the Envy IOL.
- The launch marks Bausch + Lomb’s second full range of vision premium IOL offering in Europe, alongside LuxLife.
- The Envy IOL utilizes the new EyeGility delivery system, a first for Bausch + Lomb IOLs.
The big picture
Bausch + Lomb's expansion into the European market for premium IOLs reflects the growing demand for advanced vision correction procedures globally. The introduction of enVista Envy, coupled with LuxLife, positions the company to capture a larger share of this lucrative market segment, which is increasingly driven by patient preference for minimally invasive procedures and improved visual outcomes. The company's focus on dysphotopsia mitigation is a strategic response to a key patient concern in premium IOL adoption.
What we're watching
- Market Adoption
- The success of enVista Envy in Europe will depend on surgeon adoption and patient demand, which may be influenced by competitor offerings like LuxLife.
- Clinical Data
- Continued monitoring of long-term clinical outcomes in European patients will be crucial to validate the initial U.S. and Canadian trial results and support reimbursement claims.
- Delivery System
- The performance and reliability of the EyeGility delivery system will be a key factor in surgeon satisfaction and overall adoption of the enVista Envy IOL.
Related topics